Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market

Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma

Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition

Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025

New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults

Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction

New study presents a human-relevant stress model for assessing potential therapeutics